US2021244697A1PendingUtilityA1

Compositions comprising 15-ohepa and methods of using the same

74
Assignee: AFIMMUNE LTDPriority: Jan 30, 2013Filed: Apr 16, 2021Published: Aug 12, 2021
Est. expiryJan 30, 2033(~6.6 yrs left)· nominal 20-yr term from priority
Inventors:Jonathan RoweKevin DuffyJohn Climax
A61K 31/232A61K 31/202A61P 1/16A61K 31/557A61P 1/00A61K 9/48A61K 9/0053
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.

Claims

exact text as granted — not AI-modified
I/We claim: 
     
         1 . A pharmaceutical composition comprising 15-hydroxyeicosapentaenoic acid (15-HEPE) in free acid form or a pharmaceutically acceptable ester, conjugate, or salt thereof. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition comprises 100 mg to 1000 mg of the 15-HEPE. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the 15-HEPE comprises at least about 80%, by weight, of the pharmaceutical composition. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the 15-HEPE comprises at least about 80%, by weight, of all fatty acids present in the pharmaceutical composition. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition comprises not more than about 10%, by weight of the pharmaceutical composition, of omega-3 fatty acids other than the 15-HEPE. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein omega-3 fatty acids other than the 15-HEPE comprise not more than about 10%, by weight, of all fatty acids present in the pharmaceutical composition. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the 15-HEPE is in esterified form. 
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein the esterified form is a C1-C5 alkyl ester. 
     
     
         9 . The pharmaceutical composition of  claim 7 , wherein the esterified form is an ethyl ester. 
     
     
         10 . The pharmaceutical composition of  claim 7 , wherein the esterified form is a triglyceride. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein the 15-HEPE is in salt form. 
     
     
         12 . The pharmaceutical composition of  claim 1 , wherein about 500 mg to about 1000 mg of the 15-HEPE is present in a capsule.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.